Clinical trial
An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension
NCT02906579 is registered in ClinicalTrials.gov with Cyclerion Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension
- Lead sponsor
- Cyclerion Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2016
- Completion date
- March 17, 2017
- Enrollment
- 11 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.